首页> 美国卫生研究院文献>Turkish Thoracic Journal >Evaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?
【2h】

Evaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?

机译:结节病患者血清生物标志物的评估:维斯汀是否可以作为结节病的新生物标志物?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Sarcoidosis is a chronic systemic inflammatory disease that affects multiple organ systems. The role of biomarkers in the diagnosis and prognosis of sarcoidosis is increasing. Interest in the role of adipose tissue-mediated inflammation in the pathogenesis of inflammatory diseases has increased in recent years. Visfatin is a proinflammatory adipocytokine that has been studied for several inflammatory diseases such as diabetes mellitus, obesity, and metabolic syndrome. We aimed to assess serum visfatin levels in sarcoidosis and its relationship with other markers of inflammation such as C-reactive protein (CRP), angiotensin-converting enzyme (ACE) and erythrocyte sedimentation rate (ESR).
机译:结节病是一种慢性全身性炎症性疾病,会影响多器官系统。生物标志物在结节病的诊断和预后中的作用正在增加。近年来,人们对脂肪组织介导的炎症在炎性疾病发病机理中的作用的兴趣日益增加。 Visfatin是一种促炎性脂肪细胞因子,已被研究用于治疗多种炎症性疾病,例如糖尿病,肥胖症和代谢综合征。我们旨在评估结节病中的血清visfatin水平及其与其他炎症标志物(例如C反应蛋白(CRP),血管紧张素转化酶(ACE)和红细胞沉降率(ESR))的关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号